Hemophilia Treatment Drugs Market

Transcription

1 Hemophilia Treatment Drugs Market Hemophilia Treatment Drugs Market Segmentation by Product Type - Recombinant Coagulation Factor Concentrates, Plasma derived Coagulation Factor Concentrates; Disease Indication - Hemophilia A, Hemophilia B, Others; Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Forecast

2 Table of Content Sr. No. Chapter 1 Chapter 2 Chapter 3 Chapter 4 Chapter 5 Chapter 6 Chapter 7 Chapter 8 Chapter 9 Chapter 10 Chapter 11 Chapter 12 Chapter 13 Chapter 14 Chapter 15 Content Preface Assumptions and Research Methodology Executive Summary : Global Hemophilia Treatment Drugs Market Market Overview Market Outlook Global Hemophilia Treatment Drugs Market Analysis and Forecast, by Product Type Global Hemophilia Treatment Drugs Market Analysis and Forecast, by Disease Indication Global Hemophilia Treatment Drugs Market Analysis and Forecast, by Distribution Channel Global Hemophilia Treatment Drugs Market Analysis and Forecast, by Region North America Hemophilia Treatment Drugs Market Analysis and Forecast Europe Hemophilia Treatment Drugs Market Analysis and Forecast Asia Pacific Hemophilia Treatment Drugs Market Analysis and Forecast Latin America Hemophilia Treatment Drugs Market Analysis and Forecast Middle East & Africa Hemophilia Treatment Drugs Market Analysis and Forecast Competition Landscape

3 Hemophilia Treatment Drugs Market - Snapshot Increase in R&D investment by key players for developing new drugs for the treatment of hemophilia. Rise in demand for long-acting replacement therapies and nonfactor therapies are anticipated to fuel the growth of the global market during the forecast period. Hemophilia treatment drugs market is driven by government initiatives such as nationwide network of hemophilia treatment centers (HTCs) funded by the Federal Government in the U.S. Many of the HTCs are located at major university medical and research centers. The Federal Government in the U.S. provides funds for more than 100 HTCs.

4

5 Report Highlights The global hemophilia treatment drugs market is anticipated to reach US$ 15,000 Mn by 2026, expanding at a CAGR of 5% from 2018 to Patients who are provided care and treated at HTCs are less likely to have hospitalization and bleeding complications than those who avail care elsewhere. On the basis of product type, the recombinant coagulation factor concentrates segment is expected to dominate the hemophilia treatment drugs market during the forecast period. Request For Sample

6 Continue.. North America is expected to dominate the global hemophilia treatment drugs market in the coming years. Some of the prominent players operating in the global hemophilia treatment drugs market are Pfizer, Inc., Kedrion, Shire Plc., CSL Behring, Novo Nordisk A/S Novo Nordisk A/S accounted for the second largest share of the global hemophilia treatment drugs market in 2017 due to wide range of hemophilia drugs and robust pipeline. Request For Brochure

7 Contact To know more about us, please visit our website: For sales queries or new topics us on: Thank You